Firmonertinib + SHP2 inhibitor
2L+ NSCLC with EGFR Classical Mutations
Phase 1Active
Key Facts
About ArriVent Biopharma
ArriVent Biopharma is a clinical-stage oncology company with a mission to identify, develop, and commercialize differentiated medicines from global innovation centers. Its core strategy, 'R&D Done Differently,' focuses on in-licensing high-potential, late-preclinical or early-clinical assets from partners in regions like China and South Korea, then leveraging its veteran team's expertise to rapidly advance them through global development and regulatory approval. Key achievements include initiating a pivotal Phase 3 trial for its lead asset, firmonertinib, in EGFR-mutant NSCLC, securing FDA Breakthrough Therapy Designation, and building a preclinical pipeline of novel antibody-drug conjugates (ADCs).
View full company profile